Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619224 | 0.75 | RPS6KA5 (0.45) | RPS6KA5PIM1TBK1LATS1NTRK1 | |
| SCHEMBL1085884 | 0.75 | AXL (0.55) | RPS6KA5MAPK1PIM1HASPINTBK1 | |
| SCHEMBL29598321 | 0.75 | RPS6KA5 (0.45) | RPS6KA5PIM1TBK1LATS1NTRK1 | |
| SCHEMBL14237884 | 0.75 | RPS6KA5 (0.45) | RPS6KA5TBK1LATS1NTRK1GSK3B | |
| SCHEMBL21903027 | 0.75 | RPS6KA5 (0.57) | RPS6KA5CHEK1PIM1TBK1LATS1 | |
| SCHEMBL23571474 | 0.75 | RPS6KA5 (0.45) | RPS6KA5TBK1LATS1NTRK1GSK3B | |
| SCHEMBL6502791 | 0.75 | RPS6KA5 (0.45) | RPS6KA5PIM1TBK1LATS1NTRK1 | |
| SCHEMBL3986884 | 0.72 | RET (0.36) | RPS6KA5CHEK1AURKACDK2PDPK1 | |
| SCHEMBL25404197 | 0.72 | CLK1 (0.42) | CHEK1MAPK1BRD4MAP3K11CDK2 | |
| SCHEMBL1093381 | 0.72 | RPS6KA5 (0.43) | RPS6KA5TBK1LATS1NTRK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| CN-118290428-A | Preparation method of 5-ethyl-7H-pyrrolo [2,3-d ] pyrimidine | 南京合巨药业有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-115850268-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022260336-A2 | NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME | 퓨쳐메디신 주식회사 | 2022-12-15 | — | — | WO | disclosed |
| EP-4069369-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| CN-101180297-A | Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1814883-A1 | BICYCLIC INHIBITORS OR RHO KINASE | Vertex Pharmaceuticals Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| WO-2006058120-A1 | BICYCLIC INHIBITORS OR RHO KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | RPS6KA5 1067/4885CHEK1 1887/4885MAPK1 1395/4885 |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | RPS6KA5 205/4885CHEK1 70/4885MAPK1 150/4885 |
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | ROCK1, ROCK2, RHOA | RPS6KA5 271/4885CHEK1 703/4885MAPK1 285/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | RPS6KA5 89/4885CHEK1 174/4885MAPK1 1174/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | RPS6KA5 871/4885CHEK1 3559/4885MAPK1 691/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | RPS6KA5 1934/4885CHEK1 1372/4885MAPK1 1148/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | RPS6KA5 754/4885CHEK1 794/4885MAPK1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.